Illlumina said Tuesday that it has acquired data analysis firm Edico Genome.
Edico markets its DRAGEN platform, which uses field programmable gate array technology in combination with proprietary software algorithms to reduce data footprint and enable faster speeds. Users can run DRAGEN on site, in the cloud or in a hybrid mode, and can use a variety of different cloud storage solutions and analysis pipelines.
“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” Susan Tousi, senior vice president of product development at Illumina, said in a statement.
Edico President and CEO Pieter van Rooyen added, “As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing.”
Stephen Kingsmore’s group at Rady Children’s Institute for Genomic Medicine has been using Edico’s DRAGEN to speed up the time-to-diagnosis for its whole-genome sequencing pipeline for critically ill infants in the NICU and has developed a rapid protocol that take just under 24 hours.
Financial details of the acquisition were not disclosed.
Source: genomeweb
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
